A lifesaving prescription means nothing if it can’t be filled. Across h, failing to fill necessary prescriptions is quietly turning opioid addiction treatment into an illusion of care. For veterans, the consequences are not abstract. They are seen in preventable overdoses and lives lost.
Louisian policymakers have worked in recent years to expand access to medications for opioid use disorder, MOUD, most commonly buprenorphine dispensed through pharmacies. These medications are the most effective, evidence-based treatment for a chronic brain disease that alters decision-making and impulse control.
Ensuring access to MOUD remains a of the Trump administration because these medications save lives and reduce criminal recidivism. Yet one critical breakdown is often overlooked: pharmacies.
Recent data compiled for the h Department of Health reveals an alarming pattern. In each of the state’s eight pharmacy regions, between 22% and 39% of pharmacies reported zero MOUD claims, meaning they dispensed none of these medications. The result is a growing landscape of addiction treatment deserts, where care exists in theory but not in practice.
h continues to have one of the nation’s highest overdose death rates, underscoring the urgency of expanding lifesaving treatment. Yet patients can leave a doctor’s office with a valid prescription and still find no pharmacy willing or able to fill it.
Veterans face a disproportionately deadly burden in the opioid crisis; they are to die from opioid overdose as nonveterans. Chronic pain, post-traumatic stress disorder and greater opioid exposure dramatically elevate their risk of addiction. The U.S. Department of Veterans Affairs has made MOUD a central component of its response to the opioid epidemic because the medication reduces the risk of fatal overdose and improves treatment outcomes.
But even the VA cannot overcome a fragmented pharmacy network. In rural h, veterans often travel long distances for care, only to find no nearby pharmacy willing or able to fill their medication. These barriers to treatment are especially dangerous because opioid use disorder alters brain chemistry and function, making cravings harder to control and increasing the risk of relapse and overdose. That risk is even greater today, as the illicit drug supply is increasingly contaminated with fentanyl, a synthetic opioid far more potent than heroin.
So why are so many pharmacies not dispensing MOUD?
Fear of Drug Enforcement Administration scrutiny is a primary barrier. While MOUD is legal when prescribed appropriately, pharmacies must ensure prescriptions are for legitimate medical use under federal law. In practice, many interpret this standard too cautiously, concerned that dispensing MOUD or being linked to diversion cases could trigger DEA audits or investigations, even when prescriptions are valid. As a result, limit or avoid stocking and dispensing these medications.
Stigma compounds the problem, with MOUD often incorrectly viewed as substituting one addiction for another. Reimbursement challenges, along with supply constraints stemming from wholesalers’ and distributors’ concerns about DEA oversight, further limit access to these medications.
Guidance from the DEA is clear: Neither federal law nor regulations limit how much MOUD pharmacies can order or dispense. Yet in practice, access is still being choked off by the very supply chain meant to deliver care.
In a cruel irony, three of the nation’s largest drug wholesalers, operating under the nationwide opioid settlement, have imposed opaque ordering limits on buprenorphine. To avoid triggering these thresholds, many pharmacies keep inventories artificially low or stop dispensing the medication altogether.
This is how treatment fails: not in the doctor’s office, but at the pharmacy counter.
The science is settled. MOUD is the standard of care for a chronic illness, no different from insulin for diabetes or inhalers for asthma. Yet stigma, confusion and regulatory fear block access.
Fixing the problem requires alignment and accountability. Pharmacies and distributors must follow DEA guidance, not hidden quotas, and be transparent about whether they dispense MOUD. Pharmacists need clear education on dispensing requirements, and regulators must hold providers accountable when legitimate prescriptions are denied.
The DEA should also provide explicit reassurance that pharmacies acting in good faith will not face sanctions or heightened scrutiny simply for ordering or dispensing buprenorphine. Providing regulatory certainty would reduce defensive practices throughout the supply chain and help ensure pharmacies can consistently meet legitimate patient demand.
Veterans have already fulfilled their obligation to serve. Access to effective addiction treatment should not depend on geography, stigma or whether a local pharmacy can obtain the medication they need. It requires a healthcare system that delivers care all the way to the pharmacy counter.
That is the standard veterans — and every patient with opioid use disorder — deserve. h cannot afford to settle for anything less.